An Investigation of the Impact of Localized Topical Anesthesia of the Ocular Surface on End-of-day Contact Lens Discomfort

Visual Acuity Clinical Trial

Official title:

An Investigation of the Impact of Localized Topical Anesthesia of the Ocular Surface on End-of-day Contact Lens Discomfort

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03733899
• Other study ID #: CR-6292
• Status: Completed
• Phase: N/A
• Start date: November 7, 2018
• Est. completion date: February 7, 2019

Study information

• Verified date: February 2020
• Source: Johnson & Johnson Vision Care, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a controlled, randomized, subject-masked, 3x3 crossover, non-dispensing, contralateral study. Twenty subjects will be recruited based on their scores (with their habitual lenses) from the Contact Lens Dry Eye Questionnaire-8 and examined on four occasions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: February 7, 2019
• Est. primary completion date: February 7, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Potential subjects must satisfy all of the following criteria to be enrolled in the study:

1. They are of legal age (18 years) and capacity of volunteer.

2. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.

3. They must appear able and willing to adhere to the instructions set forth in this clinical protocol.

4. They have worn the same brand of soft spherical contact lenses for at least the previous three months, by self-report.

5. They are defined as 'symptomatic' contact lens wearers (CLDEQ-8 score of 20-37) with their habitual contact lenses.

6. They are willing to wear their lenses for approximately 14 hours on study days.

7. They have a wearable pair of spectacles, if applicable.

8. They agree not to participate in other clinical research for the duration of this study.

9. They can attain high contrast logMAR visual acuity of 0.20 or better in their habitual contact lenses in each eye.

Exclusion Criteria:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:

1. They have an ocular disorder, which would normally contra-indicate contact lens wear.

2. They have a systemic disorder, which would normally contra-indicate contact lens wear.

3. They are using any topical medication such as eye drops or ointment.

4. They have had cataract or corneal refractive surgery.

5. They are pregnant or breast-feeding by self-report.

6. They have any infectious disease (e.g. hepatitis) or any immunosuppressive disease (e.g. HIV), by self-report.

7. They have any known hypersensitivity or allergic reaction to any of the known ingredients in the anesthetic.

8. They have a history of severe allergic reaction or anaphylaxis.

9. They have a history of cardiac disease or hyperthyroidism.

10. They have taken part in any other contact lens or care solution clinical trial or research, within two weeks prior to starting this study.

11. They are an employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).

12. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.

13. They have grade 3 or greater of any of the following ocular surface signs which would contraindicate contact lens wear: corneal edema, corneal vascularisation, corneal staining, tarsal conjunctival changes or any other abnormality which would normally contraindicate contact lens wear.

Related Conditions & MeSH terms

• Visual Acuity

Intervention

Diagnostic Test:
• Local Anesthesia
Minims Proxymetacaine hydrochloride Eye Drops
• Placebo
Sodium Chloride Solution

Locations

Country	Name	City	State
United Kingdom	The University of Manchester	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Vision Care, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subjective Comfort Scores	Subjects were asked to rate how comfortable each eye was overall using a visual analog scale of 0 to 100 where 0=worse comfort imaginable and 100=best comfort imaginable.	5 and 10 Minutes post-treament
Primary	Change in Subjective Comfort Scores From Pre-treatment to Post-treatment	Subjects were asked to rate how comfortable each eye was overall using a visual analog scale of 0 to 100 where 0=worse comfort imaginable and 100=best comfort imaginable. Subjects wore their habitual contacts during the pre-treatment assessment.	14-Hours upon Lens-Insertion (pre-treatment), and 10 Minutes post-treament
Primary	Subjective Comfort Score Difference Between Post-treatment and Post-insertion Within Anesthetic	Subjects were asked to rate how comfortable each eye was overall on the scale of 0 to 100 where 0=worse comfort imaginable and 100=best comfort imaginable.	Immediately after lens-insertion, 5 and 10 minutes post-treatment
Secondary	Change in Subjective Comfort Between Ocular Regions at Posttreatment Within Anesthetic	Subjects were asked to rate how comfortable each eye was overall on the scale of 0 to 100 where 0=worse comfort imaginable and 100=best comfort imaginable.	5 and 10 minutes post treatment
Secondary	Change in Subjective Comfort From Pre-treatment to Post-Treatment Between Ocular Regions	Subjects were asked to rate how comfortable each eye was overall on the scale of 0 to 100 where 0=worse comfort imaginable and 100=best comfort imaginable.	14 hours upon lens-insertion (pre-treatment), 5- and 10- minutes post-treatment
Secondary	Subjective Comfort Difference Between Post-removal and Preinsertion Within Anesthetic and Cornea	Subjects were asked to rate how comfortable each eye was overall on the scale of 0 to 100 where 0=worse comfort imaginable and 100=best comfort imaginable.	Immediately before lens-insertion (pre-insertion), 30 seconds after lens removal